LGI1 and encephalitis: Clinically, therapies targeting B cells have led to better clinical outcomes than general immunosuppression with corticosteroids in MuSK-MG and anti-LGI1 encephalitis, therefore we conclude that IgG4-AID may require different treatment strategies than classical antibody-mediated autoimmunity.